Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
07/2003
07/02/2003CN1426815A Film forming liquid composition
07/02/2003CN1112933C Anti-fungal methods and materials
07/02/2003CN1112925C Neuroprotective agents
07/01/2003US6586582 Human GABA receptor proteins and polynucleotides encoding the same
07/01/2003US6586578 Deformylase (def1); isolated polynucleotide of given sequence; detects Staphylococcus aureus; can use to screen for antibiotics
07/01/2003US6586571 Isolated polypeptide that binds to MORT-1 (mediators of receptor toxicity) protein
07/01/2003US6586478 Methods and compositions for improving sleep
07/01/2003US6586476 Methods for the treatment of nephro-disorders using aminothiol compounds
07/01/2003US6586472 Treatment of rosacea using lipoic acid
07/01/2003US6586458 Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
07/01/2003US6586457 Administering to a mammal for inhibiting bone resorption a therapeutically effective amount of an EP4 receptor subtype antagonist which is a 1,2,4-triazole-3-one derivative
07/01/2003US6586455 Treatment of liposarcomas using a combination of thiazolidinediones and retinoid X receptor selective agonists
07/01/2003US6586448 Cholesteryl ester transfer protein inhibitors used as antilipemic agents for prophylaxis of cardiovascular disorders
07/01/2003US6586438 Low dose combination of metformin and another antidiabetic agent such as glyburide; side effect reduction; for first line therapy in treating diabetes
07/01/2003US6586430 Administering azabicyclo compounds to treat human immunodeficiency virus infections and respiratory system disorders
07/01/2003US6586428 Combined preparations comprising morpholine anthracyclines and anticancer agent
07/01/2003US6586425 Administering a non-corneotoxic ophthalmic preparation which affects the actin filaments of the eye; macrolides such as latrunculin-A, latrunculin-B, swinholide-A, and jasplakinolide
07/01/2003US6586424 Anticancer agents; anticholesterol agents
07/01/2003US6586423 Tyrosine kinase inhibitors
07/01/2003US6586413 Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists
07/01/2003US6586404 Pharmaceutical preparations of glutathione and methods of administration thereof
07/01/2003US6586400 Human therapeutic uses of BPI protein products
07/01/2003US6586397 Polypeptides encoding tyrosine kinase containing immunoglobulin and endithelial growth factor homology domains; induce vascularization
07/01/2003US6586391 Method of ameliorating erectile dysfunction
07/01/2003US6586257 Detecting physico-chemical property of samples disposed on a platform using a detector having an adjustable parameter; storing information and adjusting parameters based on the information; use in high throughput drug screening
07/01/2003US6586191 Isolated nucleic acids encoding mammalian galanin receptors, isolated galanin receptor proteins, vectors comprising isolated nucleic acid encoding a mammalian galanin receptor, cells comprising such vectors, antibodies directed to a
07/01/2003US6586179 Human Eag2
07/01/2003US6586015 Use of Phyllanthus for treating chronic inflammatory and fibrotic processes
07/01/2003US6585997 Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds
07/01/2003US6585995 Administering to a subject to inhibit a vaso-occlusive event an agent that reduces platelet counts in the subject in an amount effective to reduce platelet count in the subject to at least a low normal level
07/01/2003US6585987 Mixing carnitine or acylcarnitine and hyaluronic acid together in a solvent of ethanol and/or phosphate-buffered saline, sonicating, centrifuging and separating into two phases, and discarding the upper phase; and recovering complex
07/01/2003US6585970 Method for treating hypothyroidism
07/01/2003CA2166243C Apoptosis-modulating composition containing a factor modifying intracellular methional and malondialdehyde rates
06/2003
06/26/2003WO2003052408A1 Method of screening drug
06/26/2003WO2003052138A2 Methods of detecting modification of genetic material
06/26/2003WO2003052106A1 Method of screening compounds
06/26/2003WO2003052089A1 Disruption of the glutathione s-transferase-omega-1 gene
06/26/2003WO2003052048A2 Nucleic acid-associated proteins
06/26/2003WO2003051921A1 Chemokine mutants acting as chemokine antagonists
06/26/2003WO2003051917A2 Novel death associated proteins of the thap family and related par4 pathways involved in apoptosis control
06/26/2003WO2003051905A2 Taojiks as modifiers of the beta-catenin pathway and methods of use
06/26/2003WO2003051900A1 Derivatives of isoindigo, indigo and indirubin and use in treating cancer
06/26/2003WO2003051889A1 A novel sordarin derivative isolated from culture fermentations and functions as an antifungal agent
06/26/2003WO2003051886A1 Pyrazolopyridazine derivatives
06/26/2003WO2003051868A1 Lactams as tachykinin antagonists
06/26/2003WO2003051842A2 Compositions decreasing activity of hormone-sensitive lipase
06/26/2003WO2003051841A2 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase
06/26/2003WO2003051840A1 Pyrrolidine and piperidine derivates as nk1 antagonists
06/26/2003WO2003051833A2 Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5
06/26/2003WO2003051831A2 Protease inhibitors of the coagulation cascade isolated from dysidea sponges
06/26/2003WO2003051826A1 3-phenyl-2-arylalkylthiopropionic acid derivatives as selective agonists of ppar-alpha
06/26/2003WO2003051822A1 Substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor alpha (ppar)
06/26/2003WO2003051821A1 Substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor alpha (ppar)
06/26/2003WO2003051454A2 Methods for particle-assisted polynucleotide immunization using a pulsed electric field
06/26/2003WO2003051400A1 Pharmaceutical conjugates with enhanced pharmacokinetic characteristics
06/26/2003WO2003051384A1 Method for treating cervical cancer
06/26/2003WO2003051380A2 Compositions containeing curcuma extracts for the treatment of neurocerebrovascular disorders
06/26/2003WO2003051378A2 Pharmaceutical composition for topical treatment of skin disorders and skin wounds
06/26/2003WO2003051373A1 Liquid bisphosphonate formulations for bone disorders
06/26/2003WO2003051371A1 Composition of estrogen and other hormones with ascorbate, lysine, proline and other substances
06/26/2003WO2003051370A1 Selective dopamine d3 receptor agonists for the treatment of sexual dysfunction
06/26/2003WO2003051361A1 Use of hiv-1 protease inhibitors and their derivatives in the treatment of inflammation
06/26/2003WO2003051358A1 Hydroxyphenyl-pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
06/26/2003WO2003051356A1 Method for treating circadian rhythm disruptions
06/26/2003WO2003051352A1 Aminoalkyl-benzofuran-5-ol compounds for the treatment of glaucoma
06/26/2003WO2003051350A1 Use of lipoxin analogs to promote cell defense against gram-negative infections
06/26/2003WO2003051346A2 Use of selective pde5 inhibitors for treating partial and global respiratory failure
06/26/2003WO2003051344A1 Methods of inducing ovulation_using a non-polypeptide camp level modulator
06/26/2003WO2003051340A1 New film coating
06/26/2003WO2003051333A1 Reverse-micellar delivery system for controlled transportation and enhanced absorption of agents
06/26/2003WO2003051328A1 Solid dose micro implant
06/26/2003WO2003051315A2 Heteroaryl substituted triazole modulators of metabotropic glutamate receptor-5
06/26/2003WO2003051313A2 Prevention and treatment of oxidative stress disorders by glutathione and phase ii detoxification enzymes
06/26/2003WO2003051307A2 Materials and methods for the treatment or prevention of obesity
06/26/2003WO2003051304A2 Bioadhesive drug delivery system with enhanced gastric retention
06/26/2003WO2003051302A2 Methods and compositions for treatment of central nervous system disorders
06/26/2003WO2003051301A2 USE OF dsRNAs IN STRATEGIC THERAPEUTIC INTERVENTION OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY
06/26/2003WO2003051300A2 Metal complexes and formulations of rifamycin analogues and uses therof
06/26/2003WO2003051299A2 Sulfhydryl rifamycins and uses thereof
06/26/2003WO2003051293A2 Antidiabetic formulation and method
06/26/2003WO2003051287A2 Topical compositions and methods for treatment of adverse effects of ionizing radiation
06/26/2003WO2003051278A2 Nanoparticle delivery vehicle
06/26/2003WO2003051182A2 Compositions and methods for diagnosing and treating diabetes, insulin resistance and dyslipidemia
06/26/2003WO2003051180A2 METHODS AND COMPOSITIONS FOR TREATING HEMATOLOGICAL DISORDERS USING 252, 304, 19870, 14717, 9941, 19310 and 17832
06/26/2003WO2003026610A3 Process for the preparation of fast dissolving dosage form
06/26/2003WO2003014153A8 Cellular virus receptors and methods of use.
06/26/2003WO2003000721A3 Mycobacterial antigens expressed under low oxygen tension
06/26/2003WO2002098352A3 PHARMACEUTICAL COMPOSITIONS FOR THE COORDINATED DELIVERY OF NSAIDs
06/26/2003WO2002094202A3 Methods for protecting allogeneic islet transplant using soluble ctla4 mutant molecules
06/26/2003WO2002090515A3 Compositions and methods for reducing cytotoxicity and inhibiting angiogenesis
06/26/2003WO2002058733A3 Combinations of bile acid sequestrant(s) and sterol absorption inhibitor(s) and treatments for vascular indications
06/26/2003WO2002046385A3 Enzymes
06/26/2003WO2002032378A9 Fusion cells and cytokine compositions for treatment of disease
06/26/2003WO2002018608A3 Methods for enhancing the efficacy of cancer therapy
06/26/2003WO2002016597A3 Lipid metabolism enzymes
06/26/2003US20030121073 Use of acetoacetyl-CoA thiolase for identifying new fungicidally active substances
06/26/2003US20030120306 Method and apparatus for the detection and occlusion of blood vessels
06/26/2003US20030120224 Feminine care products for the delivery of therapeutic substances
06/26/2003US20030120196 Electrically activated substance and method for making the same
06/26/2003US20030120074 Cardioprotective phosphonates and malonates
1 ... 692 693 694 695 696 697 698 699 700 701 702 703 704 705 706 707 708 709 710 711 712 ... 1151